Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Nurix Therapeutics logo — Nurix is writing medicine’s next chapter using targeted prot...

Nurix Therapeutics

Nurix is writing medicine’s next chapter using targeted protein degradation as a new script to outmatch disease.

Founded 2012 United States Brisbane, United States 370 employees IPO Total: $759.15M Biotechnology

General Information

Company Name Nurix Therapeutics
Founded Year 2012
Location United States Brisbane, United States +2
Employees 370
Industries Biotechnology
Funding Stage IPO
Social

Get notified when Nurix Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Nurix Therapeutics is experiencing a period of significant strategic growth, highlighted by a new global collaboration with Roche to co-develop and commercialize a key degrader-based medicine. This major partnership, alongside recent substantial post-IPO equity financing rounds, validates their targeted protein degradation platform and provides significant resources for pipeline advancement. The company's ongoing hiring efforts further indicate an expansion of capabilities to capitalize on these strategic initiatives and accelerate their clinical programs.

Signal Types
Partnership Funding Hiring
Strategic Labels
Strategic Partnership Pipeline Acceleration Post-IPO Growth
Next Move: Clinical Trials
·
Impact: 9/10
·
Ideal For: Biopharma Investors — Post-IPO Growth

About Nurix Therapeutics

Nurix Therapeutics, founded in 2012, is a United States-based biotechnology firm set on revolutionizing medical treatments through targeted protein degradation. Their slogan, "Nurix is writing medicine’s next chapter using targeted protein degradation as a new script to outmatch disease," reflects their pioneering approach in utilizing the cell's natural ubiquitin-proteasome system.

Nurix aims to circumvent the constraints of existing therapies by developing degrader-based medicines. Their innovative platform is attracting significant interest as it promises new therapeutic solutions to previously intractable diseases.

Having successfully secured a $413.65M post-IPO equity investment as of March 1, 2026, Nurix stands well-positioned to accelerate research and expand its pipeline. The absence of named investors in recent funding rounds suggests a diversified interest from a broad array of venture capitalists and institutional backers.

Taxonomy: targeted protein degradation, degrader-based medicines, ubiquitin-proteasome system, therapeutics development, life sciences, disease treatment innovation, protein degradation machinery, pharmaceutical research, novel therapeutics, next-generation medicine

Services & Products

Development of degrader-based therapeutics
Collaborative pharmaceutical development
Clinical trial management and execution
Drug discovery utilizing DEL-AI technology

Target Customers

Patients with oncology, immunology, and neurology conditions Pharmaceutical industry partners Healthcare professionals and researchers

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Equity •••••• - 01 Mar 2026
Post Ipo Equity •••••• - 01 Apr 2024
IPO •••••• - 01 Jul 2020
Late Vc •••••• 7
Investor Investor Investor Investor Investor Investor
•••• •••• 		01 Mar 2020
Series C •••••• - 01 Sep 2015

View All 9 Funding Rounds

Nurix Therapeutics Alternatives & Competitors

View All Alternatives
Nurix Therapeutics vs
Captor Therapeutics SA
Captor Therapeutics SA Poland

Captor Therapeutics aims to treat cancer, infections, and diseases by targeting the difficult-to-dru...

IPO
79 employees
Biopharma, Biotechnology
Compare Nurix Therapeutics vs Captor Therapeutics SA
Nurix Therapeutics vs
Amphista Therapeutics Limited
Amphista Therapeutics Limited United Kingdom

A new approach to targeted protein degradation to bring life-changing medicines to patients.

Series B
48 employees
Biopharma, Biotechnology
Compare Nurix Therapeutics vs Amphista Therapeutics Limited
Nurix Therapeutics vs
TRIANA Biomedicines
TRIANA Biomedicines

A venture-backed biopharmaceutical company dedicated to discovering and developing novel therapeutic...

Also compare with: Nurix Therapeutics vs AnHorn Medicines AnHorn Medicines View all alternatives

FAQ About Nurix Therapeutics

Nurix is writing medicine’s next chapter using targeted protein degradation as a new script to outmatch disease.
Nurix Therapeutics was founded in 2012.
Nurix Therapeutics is headquartered in Brisbane, United States.
Nurix Therapeutics operates in the following industries: Biotechnology.
Nurix Therapeutics has approximately 370 employees.
Nurix Therapeutics has completed 9 funding rounds, raising a total of $759.15M. The latest funding stage is IPO.
Nurix Therapeutics offers: Development of degrader-based therapeutics, Collaborative pharmaceutical development, Clinical trial management and execution, Drug discovery utilizing DEL-AI technology.
Top alternatives and competitors to Nurix Therapeutics include Captor Therapeutics SA, Amphista Therapeutics Limited, TRIANA Biomedicines, AnHorn Medicines, Kymera Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Nurix Therapeutics and Captor Therapeutics SA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Nurix Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy